June 29, 2021 8:15 PMNEW DELHI: Five Indian generic drugmakers, including Cipla and Dr Reddy’s Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co’s anti-viral drug to treat mild Covid-19 in non-hospitalised patients in India.
The partnership gives the companies license to supply molnupiravir to India and more than 100 low- and middle-income countries following approvals or emergency authorisation by local regulatory agencies, Merck said in late April. They will then independently approach regulatory authorities for approval to manufacture and supply the drug in India.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: